How long does it take for Osimertinib (Tagressa) to become resistant to drug resistance?

Osimertinib (Osimertinib), as a targeted therapy, is usually the first- or second-line treatment for patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). Although osimertinib shows significant efficacy in the initial treatment, some patients may develop resistance over time.

Research shows that the duration of resistance to osimertinib may vary depending on individual patient differences, disease characteristics, and other factors. Some patients may develop resistance within months, while others may be able to benefit from osimertinib treatment long-term, with resistance extending to years.

However, despite the relatively long duration of resistance to osimertinib, a certain proportion of patients will eventually develop resistance. This may be due to mechanistic changes in tumor cells gradually adapting to the drug, such as new mutant forms, activation of signaling pathways, or the development of other resistance mechanisms.

In order to prolong the effective treatment time of osimertinib, researchers are conducting a series of studies and clinical trials to explore solutions in the combined application of osimertinib and other therapeutic drugs, sequential treatment options, and drug resistance mechanisms. In addition, there are a number of new therapeutic drugs under development aimed at overcoming the problem of osimertinib resistance, which may provide new treatment options for drug-resistant patients.

Therefore, although osimertinib may have a long resistance time, the patient's disease status and drug response still need to be closely monitored during treatment, and the treatment plan needs to be adjusted in a timely manner. In addition, continued research and innovation remain key to overcoming the challenge of drug resistance in lung cancer to provide more effective treatment options and improve patient survival and quality of life.